The first-in-human clinical phase I trial assessing the feasibility and safety of WDVAX, an immunostimulatory ...

Researchers at the Icahn School of Medicine at Mount Sinai have developed a first-of-its-kind mRNA system that switches on therapeutic genes preferentially inside targeted cells—an advance ...

Respiratory viruses that have diverse strains and mutate rapidly, such as influenza and COVID-19, are difficult to block ...

Glioma remains one of the most challenging malignancies of the central nervous system, characterized by a highly ...

More on AI: When it comes to folding AI tools into mammograms, AI firms believe there’s even more knowledge to be gleaned ...

The tool scans digital images of the same cancer tissue samples that pathologists use and can tell how fast the cancer is ...

Cancer continues to be one of the most challenging diseases to treat worldwide. The three main methods used to treat cancer ...

While the actor narrated an anti-vaccine documentary, he has expressed support for vaccines before, calling them a ...

Drug development in biotechnology takes time. A lot of time. On average, it takes 10 to 15 years to take a medicine from ...

In a separate development, GSK plc (NYSE:GSK) announced on November 20 that its subsidiary, TESARO, Inc., confirmed the ...

Tech and cancer researchers are publicly releasing an AI tool that can perform sophisticated tumor analysis in a fraction of ...

Microsoft and Providence Health have released GigaTIME, an open-source AI that generates virtual tumor microenvironment data ...